Biggest M&A inbound deals Japan 2023, by deal value
In 2023, the largest merger and acquisition (M&A) deal in Japan was the acquisition of Daiichi Sankyo Co Ltd (Global Development and Commercialization rights for patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd) and raludotatug deruxtecan (R-DXd), 100%) by Merck & Co Inc. The deal was worth 22 billion U.S. dollars. The second-largest deal of 2023 in Japan was the acquisition of Toshiba Corp by Japan Industrial Partners Inc TBJH Inc, worth 16 billion U.S. dollars.